Initial Testing (Stage 1) of the Polo-Like Kinase Inhibitor Volasertib (BI 6727), by the Pediatric Preclinical Testing Program

BACKGROUND: Volasertib (BI 6727) is a potent inhibitor of Polo-like kinase 1 (Plk1), that is overexpressed in several childhood cancers and cell lines. Because of its novel mechanism of action, volasertib was evaluated through the PPTP. PROCEDURES: Volasertib was tested against the PPTP in vitro cel...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pediatr Blood Cancer
Hlavní autoři: Gorlick, Richard, Kolb, E. Anders, Keir, Stephen T., Maris, John M., Reynolds, C. Patrick, Kang, Min H., Carol, Hernan, Lock, Richard, Billups, Catherine A., Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4241497/
https://ncbi.nlm.nih.gov/pubmed/23956067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24616
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky